AI-assisted, human-published
11/13/2024 /Funding Events
TRex Bio, Inc. Secures $84 Million Series B Financing Round for Advancement of Immune Therapeutics
TRex Bio, Inc. has successfully concluded an oversubscribed $84 million Series B financing round led by Delos Capital, aiming to advance its lead candidate, TRB-061, through early clinical proof of concept and support the expansion of its pipeline.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com